4.2 Illicit Drug & Cannabis Counseling

Screening for Illicit Drug Use in Primary Care

Substance use disorders represent a major public health crisis in primary care, intersecting with infectious disease transmission, mental health comorbidities, chronic pain management, and preventable overdose mortality. The U.S. Preventive Services Task Force (USPSTF) issues a Grade B recommendation that clinicians screen for illicit drug use in adults aged 18 and older, including pregnant and postpartum individuals, provided that services for accurate diagnosis, effective treatment, and appropriate care can be offered or linked.

Screening must encompass non-medical use of prescription medications (opioids, sedatives, stimulants) as well as illicit drugs (cannabis, cocaine, methamphetamine, heroin, illicit fentanyl, synthetic cannabinoids, MDMA, hallucinogens). Universal screening normalizes the clinical inquiry, decreases stigma, and prevents biased profiling.

Validated Screening Instruments

• NIDA Single-Item Screener: "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?" (A response of $\ge 1$ is positive; sensitivity ~100%, specificity ~74%).
• DAST-10 (Drug Abuse Screening Test): A 10-item self-administered or clinician-administered tool evaluating substance-related problems (excluding alcohol and tobacco). Scored 0 to 10:
  • Score 0: None (reinforce healthy behaviors; rescreen annually).
  • Score 1–2: Low risk (provide brief motivational feedback and monitoring).
  • Score 3–5: Moderate risk (conduct full clinical assessment; deliver brief intervention; consider referral).
  • Score 6–8: Substantial risk (conduct intensive assessment; refer to specialized outpatient or residential addiction treatment).
  • Score 9–10: Severe risk (urgent referral to specialized addiction medicine, medical detoxification, or inpatient care).
• WHO ASSIST (Alcohol, Smoking and Substance Involvement Screening Test): An 8-item comprehensive tool developed by the World Health Organization that calculates a substance-specific involvement score for 10 substance classes, categorizing risk as low, moderate, or high to guide clinical action.

---

Cannabis: Pharmacokinetics, Potency Trends & Cannabis Use Disorder

Cannabis is the most widely used psychoactive substance in the United States after alcohol and nicotine. The legal and commercial landscape has evolved rapidly, accompanied by dramatic increases in product potency that have fundamentally altered clinical presentations.

Modern Potency Trends & Pharmacokinetics

• Surging Delta-9-THC Concentrations: In the 1990s, typical seized cannabis flower contained 3% to 4% delta-9-tetrahydrocannabinol (THC). Contemporary commercially available flower routinely averages 15% to 30% THC, while concentrated extracts ("dabs", wax, shatter, vape cartridges) frequently contain 70% to 90%+ THC.
• Pharmacokinetics: Inhalation yields rapid alveolar absorption, with peak plasma concentrations within 10 to 30 minutes and clinical effects lasting 2 to 4 hours. Oral ingestion (edibles) undergoes variable, delayed gastrointestinal absorption and extensive hepatic first-pass metabolism to 11-hydroxy-THC (a potent psychoactive metabolite), with onset delayed by 30 to 120 minutes and duration extending 6 to 12 hours. This delay frequently prompts users to ingest repeated doses, precipitating acute intoxication, panic attacks, and toxic delirium.

Cannabis Use Disorder (CUD)

Approximately 30% of regular cannabis users develop Cannabis Use Disorder. DSM-5-TR defines CUD by the same 11 criteria as other substance use disorders (impaired control, social impairment, risky use, tolerance, and withdrawal). Severity is classified as Mild (2–3 criteria), Moderate (4–5 criteria), or Severe (6+ criteria).

Cannabis Withdrawal Syndrome

Cannabis withdrawal occurs in up to 50% of daily or near-daily users following abrupt cessation. Symptoms typically emerge within 24 to 72 hours, peak at days 2 to 6, and persist for 1 to 3 weeks:

• Psychological Symptoms: Marked irritability, anger, aggression, nervousness, anxiety, depressed mood, restlessness.
• Sleep Disturbances: Severe insomnia, vivid and bizarre dreams, nightmares.
• Physical Symptoms: Decreased appetite and significant weight loss, abdominal pain, shakiness/tremors, sweating, fever, chills, headache.
• Clinical Reassurance: Patients frequently attribute withdrawal symptoms to "rebound baseline anxiety" and resume cannabis; clinicians must educate patients that these neuroadaptive symptoms are transient.

---

Cannabinoid Hyperemesis Syndrome (CHS)

Cannabinoid Hyperemesis Syndrome is a distinct clinical entity occurring in individuals with chronic, high-dose cannabis exposure (typically daily use for $>1$ to 2 years).

Clinical Presentation & Diagnostic Triad

1. Severe, Cyclical Nausea and Intractable Vomiting: Recurrent episodes of colicky, periumbilical or epigastric abdominal pain accompanied by profuse non-bloody emesis occurring multiple times per hour, often leading to severe volume depletion, prerenal acute kidney injury, and electrolyte collapse (hypokalemia, hypochloremic metabolic alkalosis).
2. History of Chronic, Heavy Cannabis Consumption: Typically daily or near-daily consumption of high-potency cannabis products.
3. Compulsive Hot Water Bathing or Showering: A pathognomonic behavioral hallmark where patients spend hours submerged in scalding hot showers or baths, which provides transient, dramatic relief of nausea and abdominal pain.

Pathophysiology

• The Paradoxical Effect: Acute low-dose THC stimulates CB1 receptors in the dorsal vagal complex, producing antiemetic effects. However, chronic excessive exposure to high concentrations of THC down-regulates and desensitizes peripheral enteric CB1 receptors, leading to gastric hypomotility, delayed gastric emptying, and splanchnic vasodilation.
• TRPV1 Receptor Dysregulation: THC also binds and down-regulates Transient Receptor Potential Vanilloid-1 (TRPV1) receptors in the nodose ganglion and hypothalamus (the thermoregulatory center). Scalding hot water activates cutaneous TRPV1 receptors, restoring hypothalamic temperature homeostasis and diverting splanchnic blood flow to cutaneous beds ("cutaneous steal syndrome"), thereby relieving visceral pain and vomiting.

Acute Pharmacotherapy & Management

• Ineffective Standard Antiemetics: Conventional antiemetics—including ondansetron (5-HT3 antagonist), promethazine, metoclopramide, and prochlorperazine—are notoriously ineffective in CHS and frequently fail to abort symptoms.
• Topical Capsaicin Cream (0.025% to 0.075%): Highly effective first-line acute therapy. Applied as a thin film to the abdomen, back, or arms, capsaicin acts as a potent TRPV1 receptor agonist, mimicking the neurochemical relief of a hot shower. Wash hands thoroughly after application; avoid mucous membranes.
• Dopamine D2 Receptor Antagonists: Intravenous haloperidol (2.5 to 5 mg IV/IM) or droperidol (1.25 to 2.5 mg IV/IM) provides rapid, superior relief of nausea and visceral pain compared with conventional antiemetics by acting on central chemoreceptor trigger zone dopamine receptors and modulating hypothalamic signaling. Obtain baseline ECG if prolonged QTc is suspected.
• Fluid Resuscitation: Aggressive IV crystalloid rehydration and electrolyte replacement.
• Definitive Treatment: The only definitive cure is complete and permanent cessation of all cannabinoid products. Symptoms typically recur within weeks if cannabis use resumes, while full resolution occurs within 1 to 3 months of complete abstinence.

---

Cognitive, Psychiatric & Cardiovascular Adverse Effects of Cannabis

• Neurocognitive Impairment: Acute intoxication impairs working memory, attention, reaction time, and psychomotor coordination (substantially elevating motor vehicle collision risk). Heavy, adolescent-onset chronic use is associated with persistent neurodevelopmental alterations and long-term declines in executive function and IQ.
• Psychiatric Complications & Psychosis Risk: High-potency cannabis use is an established, dose-dependent risk factor for the premature onset and exacerbation of chronic psychotic disorders (e.g., schizophrenia) in genetically vulnerable individuals (such as those harboring the catechol-O-methyltransferase [COMT] Val158Met polymorphism or AKT1 risk variants). It can also precipitate acute toxic panic attacks and destabilize bipolar disorder.
• Cardiovascular Adverse Effects: Cannabis inhalation stimulates sympathetic outflow while inhibiting parasympathetic tone, inducing immediate sinus tachycardia (heart rate increases by 20% to 50%), increased myocardial oxygen consumption, and peripheral vasodilatation leading to orthostatic hypotension. Ingestion or smoking of cannabis is associated with an elevated risk of acute myocardial infarction (especially within 1 hour of use), transient ischemic attack, ischemic stroke, and malignant arrhythmias (atrial fibrillation, ventricular tachycardia) even in young patients without pre-existing coronary artery disease.

---

Stimulant Use Disorders: Cocaine & Methamphetamine

Psychostimulants are among the most devastating substances encountered in ambulatory and acute care, characterized by rapid neurochemical reinforcement, severe physical toxicity, and intense psychological dependence.

Mechanisms of Action

• Cocaine: A tropane alkaloid derived from Erythroxylum coca. Acts as a competitive inhibitor of presynaptic monoamine reuptake transporters—predominantly the Dopamine Transporter (DAT), Norepinephrine Transporter (NET), and Serotonin Transporter (SERT). In addition, cocaine acts as a local anesthetic by blocking voltage-gated cardiac sodium channels, causing QRS prolongation and pro-arrhythmic potential.
• Methamphetamine: A synthetic phenethylamine that acts not only by inhibiting DAT, NET, and SERT, but also by entering presynaptic nerve terminals via DAT and the Vesicular Monoamine Transporter-2 (VMAT-2). Methamphetamine collapses vesicular proton gradients, causing massive reverse-transport dumping of dopamine and norepinephrine directly into the synaptic cleft. Its elimination half-life is substantially longer (10 to 12 hours) compared to cocaine (60 to 90 minutes), producing prolonged neurotoxicity.

Cardiovascular Complications of Stimulants

1. Severe Hypertension & Tachycardia: Driven by massive peripheral alpha-1 and beta-1 adrenergic stimulation.
2. Acute Coronary Vasospasm & Myocardial Infarction: Intense alpha-adrenergic coronary vasoconstriction combined with increased myocardial oxygen demand, platelet hyper-reactivity, and in situ thrombus formation. Occurs even in young individuals with angiographically normal coronary arteries.
3. Aortic Dissection: Sudden, catastrophic surges in systemic blood pressure ($dP/dt$) tearing the aortic intima.
4. Accelerated Coronary Atherosclerosis: Chronic endothelial injury and smooth muscle proliferation.
5. Stimulant-Induced Dilated Cardiomyopathy: Chronic catecholamine toxicity, microvascular ischemia, and direct toxic myocarditis producing profound left ventricular systolic dysfunction with severely reduced ejection fraction.
6. Malignant Ventricular Arrhythmias: Triggered by focal ischemia, catecholamine excess, and cocaine's sodium-channel-blocking properties.

Board Exam Pearl: Management of Cocaine-Associated Chest Pain

• First-Line Pharmacotherapy: Intravenous benzodiazepines (lorazepam 1–2 mg or diazepam 5–10 mg IV) are the cornerstone of management. Benzodiazepines blunt central sympathetic outflow, reducing heart rate, blood pressure, myocardial oxygen demand, and anxiety.
• Coronary Vasospasm Relief: Sublingual or intravenous nitroglycerin and oral or IV calcium channel blockers (diltiazem) are first-line vasodilators to reverse coronary vasoconstriction and lower systemic vascular resistance.
• The Beta-Blocker Contraindication: The administration of pure, non-selective beta-blockers (e.g., propranolol) is traditionally contraindicated in acute cocaine intoxication because blocking vasodilatory beta-2 receptors allows unopposed alpha-1 adrenergic vasoconstriction, which can precipitate paradoxical malignant hypertension, severe coronary vasospasm, and acute cardiovascular collapse. While combined alpha/beta-blockers (such as labetalol) have been utilized in selected hypertensive settings, guidelines maintain that benzodiazepines, nitrates, and calcium channel blockers remain the primary evidence-based therapies.

Dental Pathology: "Meth Mouth"

Chronic methamphetamine use causes rampant, devastating oral destruction known as "meth mouth":

• Clinical Appearance: Extensive, blackened, crumbling coronal and cervical caries, severe enamel erosion, retained root tips, and advanced periodontal disease, predominantly affecting the buccal smooth surfaces and interproximal anterior teeth.
• Multifactorial Etiology:
  1. Severe Xerostomia: Alpha-2 adrenergic stimulation induces microvascular vasoconstriction in salivary glands, severely suppressing salivary flow. Saliva is essential for buffering oral acids and remineralizing enamel.
  2. Intense Bruxism and Clenching: Central dopaminergic and noradrenergic hyperstimulation produces severe trismus, jaw grinding, and structural enamel fractures.
  3. High-Sugar, Acidic Beverage Consumption: Due to extreme dry mouth and cravings for quick calories, users frequently consume large quantities of carbonated, high-sugar, acidic soft drinks.
  4. Severe Oral Hygiene Neglect: Extended periods of intoxication and acute paranoia lead to total abandonment of tooth brushing and dental care.

Neuropsychiatric & Dermatologic Complications

• Formication ("Meth Bugs" or "Speed Bumps"): Vivid tactile hallucinations of insects crawling under or on the skin. Users engage in compulsive, excoriating skin picking, resulting in scattered crusted ulcerations, scarred lesions, and secondary bacterial infections (cellulitis, Staphylococcus aureus, MRSA skin abscesses).
• Stimulant Psychosis: Persecutory paranoid delusions, hypervigilance, and auditory/visual hallucinations closely mimicking acute paranoid schizophrenia.
• The Stimulant "Crash": Following binges, presynaptic monoamine stores are profoundly depleted, triggering profound dysphoria, anhedonia, severe fatigue, hypersomnia, hyperphagia, and high acute suicide risk.
• Treatment of Stimulant Use Disorders: There are currently no FDA-approved medications for cocaine or methamphetamine use disorder. Contingency Management (CM)—an operant conditioning behavioral intervention providing tangible vouchers or prizes for objectively verified negative drug screens—holds the strongest evidence base. In the ADAPT-2 trial, the off-label combination of oral bupropion XL (450 mg/day) plus extended-release injectable naltrexone (380 mg IM every 3 weeks) demonstrated modest efficacy in reducing methamphetamine use in moderate-to-severe users.

---

Harm Reduction Principles & Essential Primary Care Interventions

Harm reduction is an evidence-based, compassionate public health approach aimed at reducing the adverse health, social, and economic consequences of substance use without demanding immediate abstinence as a mandatory condition of medical care. Primary care physicians have an ethical and clinical obligation to integrate harm reduction into everyday practice.

1. Universal Naloxone Coprescribing

Naloxone is a pure, competitive opioid receptor antagonist that rapidly reverses life-threatening opioid-induced respiratory depression:

• CDC Indications for Coprescribing Naloxone:
  • Any history of non-fatal opioid overdose.
  • Established diagnosis of Opioid Use Disorder (OUD).
  • Patients receiving high-dose prescription opioid therapy ($\ge 50\text{ Morphine Milligram Equivalents [MME]/day}$).
  • Concurrent prescription or non-medical use of benzodiazepines or other sedatives with opioids.
  • Co-occurring substance use disorders (e.g., cocaine or methamphetamine users at risk of unintended fentanyl contamination).
  • Patients with chronic kidney disease, hepatic cirrhosis, COPD, or sleep apnea receiving opioid therapy.
• Formulation & Administration: Naloxone nasal spray (4 mg/0.1 mL) administered as a single spray into one nostril. If the patient does not respond within 2 to 3 minutes, administer a second spray into the opposite nostril.
• Counseling Pearls: Educate patients, family members, and close contacts on recognizing overdose signs (unresponsiveness, pinpoint pupils, agonal breathing/apnea, cyanosis). Emphasize calling 911 immediately, administering naloxone, performing rescue breathing, and placing the individual in the recovery position. Reassure families that naloxone has zero abuse potential and causes no harm if given to someone not experiencing an opioid overdose.
• Recrudescent Toxicity Warning: The half-life of naloxone is relatively short (30 to 90 minutes). Many synthetic opioids (fentanyl analogs, methadone, extended-release formulations) have substantially longer durations of action. Patients may re-sedate and slip back into respiratory arrest once naloxone wears off, mandating emergency department evaluation.

2. Fentanyl Test Strips (FTS)

• Rationale: Illicit drug supplies in North America are heavily adulterated with illicitly manufactured synthetic fentanyl and novel analogs. Fentanyl contamination is now routinely detected not only in counterfeit prescription pills (fake "M30" oxycodone, fake Xanax) but also in non-opioid street drugs, including powder cocaine, crack cocaine, and methamphetamine.
• Counseling: Fentanyl test strips are low-cost, highly sensitive lateral-flow chromatographic immunoassays. Instruct patients to dissolve a tiny amount of substance residue (e.g., 10 mg) in water, immerse the strip for 15 seconds, and read results at 2 minutes (one line indicates fentanyl present; two lines indicate negative). Educate patients that a negative test does not guarantee safety, as novel non-fentanyl synthetic opioids (such as nitazenes) may not trigger the assay.

3. Syringe Service Programs (SSPs)

• Clinical Evidence: SSPs provide access to sterile syringes, needles, injection equipment (cookers, sterile water, cotton filters, alcohol swabs), and safe sharps disposal containers. Extensive epidemiological data confirms that SSPs reduce hepatitis C virus (HCV) and HIV transmission by over 50% without increasing community crime or drug consumption rates.
• Complication Prevention: Eliminating equipment reuse and syringe sharing directly prevents life-threatening bacterial infections, including Staphylococcus aureus tricuspid valve endocarditis, vertebral osteomyelitis, spinal epidural abscesses, and necrotizing fasciitis.
• Gateway to Recovery: Patients engaged with SSPs are five times more likely to enter substance use treatment and three times more likely to achieve sustained cessation of injection drug use compared to non-participants, serving as a non-judgmental portal into primary care and Medication for Opioid Use Disorder (MOUD with buprenorphine or methadone).

4. Destigmatizing Language in Clinical Documentation

Language directly shapes clinical care and patient engagement. Family physicians should model person-first, medically accurate terminology: